Table 2.
Intrinsic resistance and relevant therapeutic alternatives in Pseudomonas infections [159,160,161,162,163,164,165].
| Antibiotics to Which Pseudomonas Species Are Intrinsically Resistant | Antibiotics Relevant in the Therapy of Pseudomonas Infections |
|---|---|
| Glycopeptides (e.g., vancomycin) | β-lactam antibiotics: third and fourth generation parenterally administered cephalosporins (ceftazidime, cefepime, piperacillin/tazobactam), monobactams (aztreonam), carbapenems (imipenem, meropenem and doripenem), novel β-lactam/β-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/cilastatin/relebactam, meropenem/vaborbactam) |
| Daptomycin | |
| Oxazolidinones (e.g., linezolid) | |
| Macrolides (e.g., azithromycin) | |
| Lincosamides (e.g., clindamycin) | |
| Streptogramins (e.g., quinpristin-dalfopristin) | |
| Rifampin | |
| Trimethoprim-sulfamethoxazole | Fluoroquinolones: ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin |
| Tetracycline | |
| Aminopenicillins | Aminoglycosides, neoglycosides: gentamicin, tobramycin, amikacin, plazmomicin |
| Aminopenicillin/β-lactamase-inhibitor combinations | |
| I–II. generation cepalosporins | Polymyxins: colistin |
| Orally administered III generation cephalosporins |